12 weeks ombitasvir/paritaprevir-ritonavir plus ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis

Degasperi, E; Aghemo, A; Paolucci, S; D'Ambrosio, R; Borghi, M; Perbellini, R; Novazzi, F; De Nicola, S; Lunghi, G; Baldanti, F; Lampertico, P

Degasperi, E (reprint author), Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, CRC A MeA Migliavacca Ctr Liver Dis, Milan, Italy.

DIGESTIVE AND LIVER DISEASE, 2018; 50 (7): 703

Abstract

Background: Ombitasvir/paritaprevir-ritonavir (OBT/PTV-r) plus ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype 4 patients with advanc......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索